ERBB2 and breast carcinoma: In breast cancer (BC), the intrinsic molecular subtypes originally identified by gene expression profiling [11,12,13,14] and further confirmed by immunohistochemical evaluation of hormone receptors and human epithelial growth factor 2 (HER2) gene amplification [15] have quickly entered clinical practice, complementing and expanding the information provided by classical pathological markers.